Erectile dysfunction market

Erectile Dysfunction Treatment Market, By Drugs (Sildenafil (Viagra), Vardenafil (Levitra Staxyn), Tadalafil (Cialis), Avanafil (Stendra), Udenafil (Zydena), Others), By Route of Administration (Oral drugs, Injections, Topical application), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Request Free Sample

Sep 2023
CMI200
180 Pages
Excel & Pdf
Pharmaceutical

Summary

The global erectile dysfunction treatment market is estimated to be valued at US$ 4.54 Bn in 2023 and is expected to exhibit a CAGR of 7.6% during the forecast period (2023-2030).

Analysts’ Views on the Global Erectile Dysfunction Treatment Market:

The global erectile dysfunction treatment market has been steadily growing due to factors such as an aging population, changing lifestyle patterns, increased awareness, and reduced stigma associated with seeking treatment for Erectile Dysfunction (ED). Research and development in the field of ED treatment have led to the exploration of new therapies. Some of these include stem cell therapy and gene therapy.

Figure 1. Global Erectile Dysfunction Treatment Market Share (%), By Product Type, 2023

Global Erectile Dysfunction Treatment Market - Drivers

Increasing prevalence of erectile dysfunction: The increasing incidence of erectile dysfunction is expected to propel the growth of the global erectile dysfunction treatment market over the forecast period. For instance, according to an article published by Jobson Medical Information LLC which delivers comprehensive medical information and communications to the healthcare community, in June 2022, annual erectile dysfunction incidence rate increased with each decade of age and was 12.4 cases per 1,000 man-years (95% CI 9.0 to 16.9), 29.8 (24.0 to 37.0) and 46.4 (36.9 to 58.4) for men 40 to 49, 50 to 59 and 60 to 69 years old, respectively.
Increasing product launches for the treatment of erectile dysfunction by market players: Increasing product launches for the treatment of erectile dysfunction by market players which are expected to drive the global erectile dysfunction treatment market growth over the forecast period. For instance, in August 2023, Mangoceuticals, Inc., a company focused on developing, marketing, and selling, a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated Erectile Dysfunction (ED) drug branded “Mango,” announced the official commercial launch of its second Mango ED product, which leverages the company’s existing custom compound alongside Sildenafil, the active ingredient found in Viagra.

Figure 2. Global Erectile Dysfunction Treatment Market Share (%), By Region, 2023

Global Erectile Dysfunction Treatment Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global erectile dysfunction treatment market over the forecast period. North America is estimated to hold 33.9% of the market share in 2023 owing to key players operating in the market focusing on product launches. For instance, in June 2023, Futura Medical, a research and development pharmaceutical company, had developed Eroxon, a topical gel for erectile dysfunction, which has been authorized for over-the-counter marketing in the U.S.

Global Erectile Dysfunction Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of things from one place to another.
However, the COVID-19 pandemic had a negative impact on the global erectile dysfunction. Economic uncertainties caused by the pandemic have influenced consumer spending behaviors, including spending on non-essential medications or treatments such as those for erectile dysfunction.

Erectile Dysfunction Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2022	Market Size in 2023:	US$ 4.54 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 to 2030
Forecast Period 2023 to 2030 CAGR:	7.6%	2030 Value Projection:	US$ 7.57 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drugs: Sildenafil (Viagra), Vardenafil (Levitra Staxyn), Tadalafil (Cialis), Avanafil (Stendra), Udenafil (Zydena), Others By Route of Administration: Oral drugs, Injections, Topical application By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific, Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLC
Growth Drivers:	Increasing prevalence of erectile dysfunction Increasing product launches for the treatment of erectile dysfunction by market players
Restraints & Challenges:	Ban on erectile dysfunction drugs

Global Erectile Dysfunction Treatment Market Segmentation:

The global erectile dysfunction treatment market report is segmented into by drugs, by route of administration, by distribution channel, and by region.

By Drugs, the market is segmented into Sildenafil (Viagra), Vardenafil (Levitra Staxyn) , Tadalafil (Cialis), Avanafil (Stendra), Udenafil (Zydena), and others. Out of which, the Sildenafil (Viagra) segment is expected to hold a dominant position in the global erectile dysfunction treatment market during the forecast period, and this is attributed to key players operating in the market focusing on inorganic strategies to offer Sildenafil (Viagra).
By Route of Administration, the market is segmented into oral drugs, injection, and topical application. Out of which, oral drugs is expected to dominate the market over the forecast period, and this is attributed to the adoption of oral drugs as it can be self-administered and economical which drives the growth of the segment .
By Distribution Channel, the market is segmented into hospital pharmacies, offline pharmacies, and online pharmacies. Out of which, retail pharmacies is expected to dominate the market over the forecast period, and this is attributed to their easy access to medicine and availability of generic ED drugs through retail pharmacies.

Among all the segmentation, the product type segment is expected to dominate the market over the forecast period, and this is attributed to increasing inorganic and organic growth strategies by market players for the treatment of erectile dysfunction.

Global Erectile Dysfunction Treatment Market - Cross Sectional Analysis:

The key players focusing on organic growth strategies, such as product approvals for erectile dysfunction, is also expected to drive the market growth of in the North America region over the forecast period. For instance, in March 2022, Lupin Limited (Lupin) India based multinational pharmaceutical company, announced that it had received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a generic equivalent of Revatio for Oral Suspension, 10 mg/mL, of Viatris Specialty LLC, a global pharmaceutical company. Sildenafil is used to treat impotence or erectile dysfunction-ED

Global Erectile Dysfunction Treatment Market: Key Developments

In January 2020, Greenstone, is part of the Upjohn business and a wholly owned subsidiary of Pfizer Inc., and Roman, an innovative digital healthcare clinic for men, announced a supply agreement to offer Roman members access to the only U.S. FDA-approved authorized generic version of Viagra (sildenafil citrate).

In December 2020, Glenmark Pharmaceuticals Ltd. an India-based multinational pharmaceutical company, received final approval from the U.S. Food and Drug Administration (FDA) for Tadalafil tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. Tadalafil tablets are used to treat erectile dysfunction by increasing blood flow to the penis during sexual stimulation.

Global Erectile Dysfunction Treatment Market: Key Trends

Increasing awareness for erectile dysfunction treatment : Introduction of erectile dysfunction treatment with advanced technology in the market is expected to drive the growth of the global erectile dysfunction treatment market over the forecast period. For instance, in August 2021, Pfizer Upjohn, a division of Pfizer, a the biopharmaceutical company, launched a campaign, #KeepItReal, to help make conversations about Erectile Dysfunction (ED) less of a taboo for couples, enabling them to discuss their problems and find a suitable solution. The campaign is conceptualized by Edelman India, is a global communications firm that partners with businesses and organizations to evolve, promote, and protect their brands and reputations.

Global Erectile Dysfunction Treatment Market: Restraint

Ban on erectile dysfunction drugs: Ban on erectile dysfunction drugs is expected to hinder the market growth over the forecast period. For instance, in August 2022, Indiana Representative proposed an amendment to Indiana's abortion law to outlaw the sale, prescription, or distribution of erectile dysfunction drugs and other male sexual incompetence drugs.Market players should collaborate closely with regulatory agencies to understand the specific reasons for the ban and work on addressing those concerns. Present clear evidence of the drug's benefits and the steps taken to mitigate any potential risks.

Global Erectile Dysfunction Treatment Market - Key Players

The major players operating in the global erectile dysfunction treatment market include Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific , Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLC.

*Definition: Erectile Dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as men get older. But it's not a natural part of aging.

Table of Content

Table of Contents

*Browse 32 market data tables and 22 figures on “Global Erectile Dysfunction Treatment Market” – Global forecast to 2030

Segmentation

Global Erectile Dysfunction Treatment Market Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and Compound Annual Growth Rate (CAGR) of the global erectile dysfunction treatment market during the forecast period (2023-2030)?

The global erectile dysfunction treatment market is estimated to be valued at US$ 4.54 Bn in 2023 and is expected to exhibit a CAGR of 7, 6% between 2023 and 2030.

What are the major factors driving the market growth?

Increasing prevalence of erectile dysfunction and increasing product launches for the treatment of erectile dysfunction by market players is expected to drive the market growth.

Which is the leading drug segment in the market?

Ban on erectile dysfunction drug is the leading product type segment in the market.

What are the key factors hampering the growth of the market?

Ildenafil (Viagra) is expected to hinder the market growth over the forecast period.

Which are the major players operating in the market?

The major players operating in the market are Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific , Cipla Ltd, Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLLC.